EGFR and non-small cell lung carcinoma: reported that ctDNA NGS identified eight genomic biomarkers, including EGFR mutations, at a rate at least as high as that of tissue genotyping, with high tissue concordance, more rapidly and more completely than tissue‐based genotyping among 282 patients with newly diagnosed metastatic NSCLC.16